Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 450Breast Neoplasms 331Neoplasm Metastasis 244Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 190Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Squamous Cell Carcinoma of Head and Neck 111Leukemia, Lymphocytic, Chronic, B-Cell 111Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 87Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 76Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Chemotherapy-induced Neutropenia × Clear all
NCT03559387 2019-02-12

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Prolong Pharmaceuticals

Phase 2 Terminated
9 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡